Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rev-Lite: Low Dose Lenalidomide + Dexamethasone in RRMM
NCT00482261Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2007
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Overall Response Rate at 2 years. Started Jun 2007; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00482261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482261.